Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT/QTc Study of ADASUVE in Healthy Volunteers
NCT01854710Phase 4Completed
- Sponsor
- Alexza Pharmaceuticals Inc
- Start
- May 2013
- Primary completion
- Jul 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of loxapine in schizophrenia and bipolar I disorder (6 arms), sponsored by Alexza Pharmaceuticals Inc. Primary endpoint: Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo. Started May 2013; status: completed.
02
Drugs
loxapine
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on NCT01854710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01854710.